PE20230261A1 - MEDICATION/AGENT FOR THE TREATMENT OF CORONAVIRUS, RETROVIRAL INFECTIONS AND HEPATITIS C - Google Patents
MEDICATION/AGENT FOR THE TREATMENT OF CORONAVIRUS, RETROVIRAL INFECTIONS AND HEPATITIS CInfo
- Publication number
- PE20230261A1 PE20230261A1 PE2022002082A PE2022002082A PE20230261A1 PE 20230261 A1 PE20230261 A1 PE 20230261A1 PE 2022002082 A PE2022002082 A PE 2022002082A PE 2022002082 A PE2022002082 A PE 2022002082A PE 20230261 A1 PE20230261 A1 PE 20230261A1
- Authority
- PE
- Peru
- Prior art keywords
- hepatitis
- coronavirus
- drug
- treatment
- infections
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract 6
- 229940079593 drug Drugs 0.000 title abstract 4
- 241000711573 Coronaviridae Species 0.000 title abstract 2
- 206010038997 Retroviral infections Diseases 0.000 title abstract 2
- 239000003795 chemical substances by application Substances 0.000 title 1
- 208000006454 hepatitis Diseases 0.000 title 1
- 231100000283 hepatitis Toxicity 0.000 title 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 abstract 6
- 208000001528 Coronaviridae Infections Diseases 0.000 abstract 2
- 208000005176 Hepatitis C Diseases 0.000 abstract 2
- 208000030507 AIDS Diseases 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 230000002421 anti-septic effect Effects 0.000 abstract 1
- 241001493065 dsRNA viruses Species 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 229940124622 immune-modulator drug Drugs 0.000 abstract 1
- 238000002347 injection Methods 0.000 abstract 1
- 239000007924 injection Substances 0.000 abstract 1
- 230000003834 intracellular effect Effects 0.000 abstract 1
- 239000007927 intramuscular injection Substances 0.000 abstract 1
- 238000010255 intramuscular injection Methods 0.000 abstract 1
- 230000001988 toxicity Effects 0.000 abstract 1
- 231100000419 toxicity Toxicity 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/11—Aldehydes
- A61K31/115—Formaldehyde
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
La invencion se refiere a la medicina y la medicina veterinaria, y mas especificamente con la farmacologia, y puede utilizarse para tratar infecciones virales causadas por virus de ARN que tienen una envoltura lipidica, en particular infecciones coronavirales, SIDA y hepatitis C. La invencion amplia la gama de medicamentos para el fin reivindicado. El resultado tecnico es la creacion de un farmaco que tiene un efecto antiseptico intracelular que activa la produccion de formaldehido endogeno en el cuerpo de un humano y animales sin tener efectos secundarios ni toxicidad. El resultado tecnico se logra mediante el uso de un farmaco inmunomodulador que comprende 0.073-0.075% de formaldehido en una solucion isotonica de cloruro de sodio como farmaco para inyecciones intramusculares con una dosis unica de inyeccion de 5 ml para el tratamiento de infecciones coronavirales y retrovirales y hepatitis C.The invention relates to medicine and veterinary medicine, and more specifically to pharmacology, and can be used to treat viral infections caused by lipid-enveloped RNA viruses, in particular coronavirus infections, AIDS and hepatitis C. The invention broadly the range of medicines for the claimed purpose. The technical result is the creation of a drug that has an intracellular antiseptic effect that activates the production of endogenous formaldehyde in the body of a human and animals without having side effects and toxicity. The technical result is achieved by using an immunomodulatory drug comprising 0.073-0.075% formaldehyde in isotonic sodium chloride solution as a drug for intramuscular injections with a single injection dose of 5 ml for the treatment of coronavirus and retroviral infections. and hepatitis C.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2020112322A RU2738719C1 (en) | 2020-03-26 | 2020-03-26 | Agent for treating coronavirus, retrovirus infections and hepatitis c |
| PCT/RU2020/050334 WO2021194375A1 (en) | 2020-03-26 | 2020-11-19 | Drug for treating coronaviral and retroviral infections and hepatitis c |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20230261A1 true PE20230261A1 (en) | 2023-02-07 |
Family
ID=73835019
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2022002082A PE20230261A1 (en) | 2020-03-26 | 2020-11-19 | MEDICATION/AGENT FOR THE TREATMENT OF CORONAVIRUS, RETROVIRAL INFECTIONS AND HEPATITIS C |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20230090982A1 (en) |
| EP (1) | EP4074310A4 (en) |
| JP (1) | JP2023519888A (en) |
| CN (1) | CN115701990A (en) |
| BR (1) | BR112022019357A2 (en) |
| CA (1) | CA3176867A1 (en) |
| CO (1) | CO2022015272A2 (en) |
| CR (1) | CR20220546A (en) |
| CU (1) | CU20220057A7 (en) |
| IL (1) | IL296758A (en) |
| MX (1) | MX2022011976A (en) |
| PE (1) | PE20230261A1 (en) |
| RU (1) | RU2738719C1 (en) |
| WO (1) | WO2021194375A1 (en) |
| ZA (1) | ZA202211706B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2765467C1 (en) * | 2021-07-12 | 2022-01-31 | Владислав Николаевич Ласкавый | Mitochondrial dysfunction correction agent |
| WO2023244141A1 (en) * | 2022-06-15 | 2023-12-21 | Ренат Рушанович ХАБЕЕВ | Antiviral preparation for injection |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2077882C1 (en) * | 1995-11-21 | 1997-04-27 | Владислав Николаевич Ласкавый | Immunomodulating agent |
| RU2146134C1 (en) * | 1999-06-29 | 2000-03-10 | Ласкавый Владислав Николаевич | Antiviral preparation for injections |
| NZ551457A (en) * | 2004-05-14 | 2009-12-24 | Sciclone Pharmaceuticals Inc | Treatment or prevention of respiratory viral infections with immunomodulator compounds |
| MX2010009479A (en) * | 2008-02-29 | 2010-12-07 | Afexa Life Sciences Inc | Activation of innate and adaptive immune responses by a ginseng extract. |
| RU2381807C1 (en) * | 2008-07-18 | 2010-02-20 | Алексей Глебович Одинец | Antiviral agent |
| ITRM20110278A1 (en) * | 2011-06-06 | 2012-12-07 | Cavallari Ivan | PHARMACEUTICAL COMPOSITION INCLUDING FORMALDEHYDE, A SOURCE OF FORMILE IONS AND ITS USES IN MEDICAL FIELD. |
| CN103006628A (en) * | 2012-12-31 | 2013-04-03 | 刘宗山 | Application of formaldehyde in preparation of injection for treating animal and human infectious disease |
| FR3013222B1 (en) * | 2013-11-18 | 2016-09-30 | Amadeite | EXTRACT OF ALGAE FOR ITS USE AS IMMUNOMODULATOR |
-
2020
- 2020-03-26 RU RU2020112322A patent/RU2738719C1/en active
- 2020-11-19 MX MX2022011976A patent/MX2022011976A/en unknown
- 2020-11-19 US US17/798,282 patent/US20230090982A1/en not_active Abandoned
- 2020-11-19 CN CN202080100373.XA patent/CN115701990A/en active Pending
- 2020-11-19 JP JP2022558419A patent/JP2023519888A/en active Pending
- 2020-11-19 IL IL296758A patent/IL296758A/en unknown
- 2020-11-19 CA CA3176867A patent/CA3176867A1/en active Pending
- 2020-11-19 PE PE2022002082A patent/PE20230261A1/en unknown
- 2020-11-19 BR BR112022019357A patent/BR112022019357A2/en not_active IP Right Cessation
- 2020-11-19 CR CR20220546A patent/CR20220546A/en unknown
- 2020-11-19 CU CU2022000057A patent/CU20220057A7/en unknown
- 2020-11-19 WO PCT/RU2020/050334 patent/WO2021194375A1/en not_active Ceased
- 2020-11-19 EP EP20927055.2A patent/EP4074310A4/en not_active Withdrawn
-
2022
- 2022-10-26 ZA ZA2022/11706A patent/ZA202211706B/en unknown
- 2022-10-26 CO CONC2022/0015272A patent/CO2022015272A2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN115701990A (en) | 2023-02-14 |
| US20230090982A1 (en) | 2023-03-23 |
| ZA202211706B (en) | 2023-02-22 |
| BR112022019357A2 (en) | 2023-01-03 |
| EP4074310A1 (en) | 2022-10-19 |
| CO2022015272A2 (en) | 2023-01-26 |
| WO2021194375A1 (en) | 2021-09-30 |
| RU2738719C1 (en) | 2020-12-15 |
| CR20220546A (en) | 2023-06-19 |
| CU20220057A7 (en) | 2023-05-11 |
| EP4074310A4 (en) | 2024-01-10 |
| IL296758A (en) | 2022-11-01 |
| JP2023519888A (en) | 2023-05-15 |
| MX2022011976A (en) | 2022-10-20 |
| CA3176867A1 (en) | 2021-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2021008055A2 (en) | Heterocycles functionalized as antiviral agents | |
| CO2019000069A2 (en) | Antiviral agents against hepatitis b | |
| CL2021002747A1 (en) | Antiviral Agents for Hepatitis B (Divisional Application No. 487-2020) | |
| CO2022015272A2 (en) | Drug/agent for the treatment of coronavirus, retroviral infections and hepatitis c | |
| EA201892034A1 (en) | ELIMINATION OF HEPATITIS B VIRUS WITH THE HELP OF ANTI-VIRUS AGENTS | |
| EA201791872A1 (en) | POLYCYCLIC CARBAMOILPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL APPLICATIONS | |
| UY38383A (en) | HETEROCYCLES FUNCTIONALIZED AS ANTIVIRAL AGENTS | |
| PE20191650A1 (en) | INDOLINE DERIVATIVES SUBSTITUTED AS INHIBITORS OF DENGUE VIRAL REPLICATION | |
| AR070026A1 (en) | SET OF ELEMENTS FOR THE DOSAGE OF 1-AMINO-ALQUILCICLOHEXANOS, SUCH AS NERAMEXAN, AND TREATMENT OF DIFFERENT DISEASES INCLUDING TINNITUS | |
| MX2016012799A (en) | METHODS TO TREAT HEPATITIS C. VIRUS | |
| AR120399A1 (en) | A METHOD OF TREATMENT OF A DLL3 POSITIVE CANCER | |
| PA8744101A1 (en) | METHOD OF COMBINED THERAPY FOR THE TREATMENT OF INFECTION BY THE VIRUS OF HEPATITIS C AND PHARMACEUTICAL COMPOSITIONS FOR USE IN SUCH THERAPY | |
| CO2022008701A2 (en) | Use and pharmaceutical composition of phenylisoxazolyl methylene naphthalene ether derivatives | |
| PE20240881A1 (en) | USE OF AN EZH2 INHIBITOR IN THE PREPARATION OF DRUGS FOR THE TREATMENT OF T LYMPHOCYTE LYMPHOMA | |
| CO2021016606A2 (en) | Methods of administering an anti-cd38 antibody to treat multiple myeloma | |
| CO2022011666A2 (en) | Use of the compound in the prevention and/or treatment of pathogenic infections in animals | |
| BR112021025764A2 (en) | Pyrimidine derivative that inhibits the growth of cancer cells and medicinal use thereof | |
| AR119430A1 (en) | METHODS TO TREAT OR PREVENT SPINAL MUSCULAR ATROPHY | |
| MX2020005006A (en) | Coumarin derivative for therapy or prophylaxis of a cell proliferative disorder. | |
| CL2018003270A1 (en) | A pharmaceutical composition comprising carboxylic acid to treat and prevent nasal congestion. | |
| MX2021010834A (en) | Compound and method for the prevention of transmission of influenza virus. | |
| MX2015013115A (en) | NEW DOSAGE REGIMES OF CELGOSIVIR FOR THE TREATMENT OF DENGUE. | |
| CO2023017669A2 (en) | Advantageous anti-hcv combination therapy | |
| EA199901103A1 (en) | ANTI-VIRUS PREPARATION FOR INJECTIONS | |
| EA201900586A1 (en) | COMBINED DRUG FOR THERAPY OF VIRAL INFECTIONS |